Carbamazepine
Carbamazepine, Carbatrol, Epitol, Equetro, Tegretol, Teril (carbamazepine) is a small molecule pharmaceutical. Carbamazepine was first approved as Tegretol on 1982-01-01. It is used to treat bipolar disorder, complex partial epilepsy, mood disorders, post-traumatic stress disorders, and psychotic disorders amongst others in the USA. It is known to target frizzled-8.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Carbamazepine, Carbatrol, Epitol, Equetro, Tegretol, Teril (discontinued: Carbamazepine, Carnexiv, Tegretol, Teril)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carbamazepine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TEGRETOL | Novartis | N-016608 RX | 1982-01-01 | 1 products, RLD, RS |
| TEGRETOL | Novartis | N-018927 RX | 1987-12-18 | 1 products, RLD, RS |
| TEGRETOL-XR | Novartis | N-020234 RX | 1996-03-25 | 3 products, RLD, RS |
| CARBATROL | Takeda | N-020712 RX | 1997-09-30 | 3 products, RLD |
| EQUETRO | Validus Pharmaceuticals | N-021710 RX | 2004-12-10 | 3 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| carbamazepin carbamazepine | ANDA | 2023-10-19 |
| carbamazepine | ANDA | 2026-02-26 |
| carbamazepine er | ANDA | 2026-02-08 |
| carbatrol | New Drug Application | 2025-06-27 |
| carbatrol extended-release | 2007-03-30 | |
| epitol | ANDA | 2024-01-31 |
| equetro | New Drug Application | 2025-08-19 |
| hand sanitizer | OTC monograph not final | 2021-11-30 |
| tegretol | New Drug Application | 2025-12-16 |
| tegretol tegretol - xr | 2006-05-11 |
Show 1 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
HCPCS
No data
Clinical
Clinical Trials
215 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 9 | 3 | 17 | 20 | 18 | 66 |
| Healthy volunteers/patients | — | — | — | 39 | — | — | 1 | 3 | 43 |
| Seizures | D012640 | — | G40.4 | 2 | 1 | 8 | 3 | 9 | 22 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 1 | 3 | 13 | 2 | 19 |
| Partial epilepsies | D004828 | EFO_0004263 | — | 2 | — | 5 | 8 | 1 | 16 |
| Neuralgia | D009437 | EFO_0009430 | — | — | 2 | 2 | 6 | 5 | 14 |
| Trigeminal neuralgia | D014277 | EFO_1001219 | G50.0 | — | 2 | 1 | 3 | 7 | 12 |
| Depression | D003863 | — | F33.9 | — | 1 | 2 | 1 | 1 | 4 |
| Cocaine-related disorders | D019970 | — | F14 | — | 3 | — | 1 | — | 4 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | 1 | 1 | 4 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sclerosis | D012598 | — | — | — | 1 | 1 | — | 1 | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | 2 | — | — | 3 |
| Tuberous sclerosis | D014402 | — | Q85.1 | 1 | — | 1 | — | — | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 2 | — | — | 2 |
| Generalized epilepsy | D004829 | — | — | — | — | 2 | — | — | 2 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | — | 1 |
| Tonic-clonic epilepsy | D004830 | EFO_0007262 | — | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 5 | 2 | — | — | — | 6 |
| Gliosarcoma | D018316 | — | — | 5 | 2 | — | — | — | 6 |
| Astrocytoma | D001254 | EFO_0000271 | — | 4 | 1 | — | — | — | 4 |
| Central nervous system neoplasms | D016543 | — | — | 1 | 2 | — | — | — | 2 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 2 | 1 | — | — | — | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | 1 | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 1 | — | — | — | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | — | — | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | — | 1 |
| Alpha 1-antitrypsin deficiency | D019896 | — | E88.01 | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioma | D005910 | EFO_0000520 | — | 4 | — | — | — | — | 4 |
| Covid-19 | D000086382 | — | U07.1 | 3 | — | — | — | — | 3 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
| Hepatitis b | D006509 | — | — | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Cancer pain | D000072716 | — | G89.3 | 1 | — | — | — | — | 1 |
| High-intensity focused ultrasound ablation | D057086 | — | — | 1 | — | — | — | — | 1 |
| Hot flashes | D019584 | — | — | 1 | — | — | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | — | — | 2 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 2 | 2 |
| Financial stress | D000086522 | — | — | — | — | — | — | 1 | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 1 | 1 |
| Metabolic bone diseases | D001851 | — | — | — | — | — | — | 1 | 1 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 1 | 1 |
| Drug hypersensitivity | D004342 | EFO_0009482 | T88.7 | — | — | — | — | 1 | 1 |
| Drug hypersensitivity syndrome | D063926 | EFO_1002004 | D72.12 | — | — | — | — | 1 | 1 |
Show 21 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Carbamazepine |
| INN | carbamazepine |
| Description | Carbamazepine is a dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant. It has a role as an anticonvulsant, an EC 3.5.1.98 (histone deacetylase) inhibitor, a mitogen, a glutamate transporter activator, an antimanic drug, an analgesic, a non-narcotic analgesic, an environmental contaminant, a xenobiotic, a drug allergen and a sodium channel blocker. It is a dibenzoazepine and a member of ureas. |
| Classification | Small molecule |
| Drug class | tricyclic compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)N1c2ccccc2C=Cc2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 298-46-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL108 |
| ChEBI ID | 3387 |
| PubChem CID | 2554 |
| DrugBank | DB00564 |
| UNII ID | 33CM23913M (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Carbatrol – Shire
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Carbamazepine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Carbamazepin carbamazepine, Carbamazepine, Carbamazepine er, Carbatrol, Carbatrol extended-release, Epitol, Equetro, Tegretol, Tegretol tegretol - xr
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
49,387 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use